You are here

Single domain antibodies as medical countermeasures for viral induced encephalitis

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: W911QY-16-P-0229
Agency Tracking Number: C161-004-0062
Amount: $149,656.59
Phase: Phase I
Program: SBIR
Solicitation Topic Code: CBD161-004
Solicitation Number: 2016.1
Solicitation Year: 2016
Award Year: 2016
Award Start Date (Proposal Award Date): 2016-06-14
Award End Date (Contract End Date): 2016-12-13
Small Business Information
321 Jones Boulevard
Pottstown, PA 19464
United States
DUNS: 962964990
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Rolf Swoboda, PhD
 (610) 990-7531
Business Contact
 Hiep Tran, PhD
Phone: (610) 990-7531
Research Institution

Alphavirus infection, which may cause encephalitis and death, are recognized as potential biological warfare agents. There are no approved medical countermeasures against diseases caused by Alphaviruses. In this project, thermostable single domain antibodies capable of crossing the blood brain barrier (BBB) and neutralizing encephalitic viruses will be developed using Abzymes proprietary in vivo Self-Diversifying Camelid Single Domain Antibody Library (SDALib) platform.Camelid SDALib will provide a diverse array of single domain antibodies, without the need for animal immunization.Since this is a non-animal system, the platform can generate diverse antibodies against toxins, pathogens, self-antigens, and the like which are by nature difficult to obtain.In Phase I, high-affinity single domain antibodies targeting equine encephalitis virus-like particles (VLP) will be developed.The ability of isolated single domain antibodies to cross blood-brain barrier will be demonstrated using an in vitro BBB system.In Phase II, antibody candidates will be humanized and further evaluated as a medical countermeasure against viral infection in a small mammal study.Antibodies from selected clones will be produced in large quantity.Non-clinical GLP pharmacokinetic and pharmacodynamics data will be obtained laying the foundation for subsequent Phase III studies.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government